ONE MILESTONE PASSED – NOW WE LOOK FORWARD During the quarter, we reached an important milestone when we were finally able to approve our product in chromatography – NLAB Saga® – and after that make the first delivery to a customer who will use it in their production of insulin. The fine-tuning of the production that we implemented at the beginning of the year were successful, and on May 3 we were able to approve
Fine-tuning production The company’s absolute top priority in the beginning of the year has continued to be production. We have implemented fine-tunings in one of the process steps and evaluation of these is ongoing. We remain committed to ensuring that our product within preparative chromatography, NLAB Saga®, maintains the highest quality over time, and we will not deliver to customers until we are completely satisfied with the product. Even though it is taking more time
Closer to a commercial break-through In 2022, Nanologica has taken several steps forward – we launched our product in preparative chromatography, took our first orders for this product and listed the company on Nasdaq Main Market. We did not reach the goal of delivering products, but have gradually come closer. We are committed to achieving a commercial breakthrough in 2023. 2022 has been characterized by an unstable situation in the world and great uncertainties in
FOCUS ON PRODUCTION A continued focus on production has characterized both the fourth quarter and the beginning of the new year. At the same time, our view of the market needs for additional suppliers of high-quality silica for preparative chromatography was strengthened. During the fourth quarter, our main focus has continued to be on production. We manufacture silica on a large scale and as we previously have described, we are satisfied with our product, but
WELL-POSITIONED FOR THE NEXT PHASE Our focus during the third quarter has mainly been on production and financing. We are now producing on a large scale in our production line, while having secured financing to intensify our investments in preparative chromatography and deliver on the order book we are starting to build. During the third quarter, we received several orders for the evaluation of NLAB Saga®, our silica for preparative chromatography, including one order from
In 2022, Nanologica has taken important steps forward in the chromatography business area. We have scaled up the production of our commercial silica for preparative chromatography, NLAB Saga®, to tonal scale, and we have sold the first products in preparative chromatography, as well as taken orders for NLAB Saga® for production-scale evaluation from one of the world’s largest insulin manufacturers. The fact that we now have products from our large-scale production means that we can
